DK3258938T3 - Phenothiazinanaloger som mitokondrie terapeutiske midler - Google Patents
Phenothiazinanaloger som mitokondrie terapeutiske midler Download PDFInfo
- Publication number
- DK3258938T3 DK3258938T3 DK16752964.3T DK16752964T DK3258938T3 DK 3258938 T3 DK3258938 T3 DK 3258938T3 DK 16752964 T DK16752964 T DK 16752964T DK 3258938 T3 DK3258938 T3 DK 3258938T3
- Authority
- DK
- Denmark
- Prior art keywords
- mitocondries
- analoges
- phenothiazine
- therapeutic medicines
- medicines
- Prior art date
Links
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229950000688 phenothiazine Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117205P | 2015-02-17 | 2015-02-17 | |
| PCT/US2016/018233 WO2016133995A1 (en) | 2015-02-17 | 2016-02-17 | Phenothiazine analogues as mitochondrial therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3258938T3 true DK3258938T3 (da) | 2021-02-01 |
Family
ID=56692740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16752964.3T DK3258938T3 (da) | 2015-02-17 | 2016-02-17 | Phenothiazinanaloger som mitokondrie terapeutiske midler |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10472340B2 (https=) |
| EP (1) | EP3258938B1 (https=) |
| JP (3) | JP6807337B2 (https=) |
| AU (3) | AU2016220096B2 (https=) |
| CA (1) | CA2976776C (https=) |
| DK (1) | DK3258938T3 (https=) |
| WO (1) | WO2016133995A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10472340B2 (en) | 2015-02-17 | 2019-11-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted phenothiazines as mitochondrial agents |
| AU2016220153B2 (en) | 2015-02-17 | 2020-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| WO2017218537A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting |
| US12570622B2 (en) | 2016-08-25 | 2026-03-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| US10745366B2 (en) | 2016-08-25 | 2020-08-18 | Arizon Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| WO2018129411A1 (en) * | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| FR3063495B1 (fr) | 2017-03-02 | 2019-04-05 | Provepharm Life Solutions | Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium |
| CN108484527B (zh) * | 2018-04-27 | 2022-01-14 | 成都恒昊创新科技有限公司 | 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用 |
| AU2019311859B2 (en) | 2018-07-22 | 2025-12-18 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| FI4385512T3 (fi) * | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| US12110313B2 (en) | 2019-02-28 | 2024-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Engineered bacterial ribosome compositions and methods |
| EP4291552B1 (en) * | 2021-02-09 | 2025-04-09 | Boehringer Ingelheim International GmbH | Modulators of complex i |
| CN119504646A (zh) * | 2024-11-07 | 2025-02-25 | 长春工业大学 | 新型含有吩噻嗪结构药物小分子的合成及抗肿瘤活性研究 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3476722A (en) | 1966-08-15 | 1969-11-04 | Goodrich Co B F | Process for polymerizing acrylic acid esters |
| DE2315349A1 (de) | 1973-03-28 | 1974-10-03 | Bayer Ag | Nicht verfaerbende alterungsschutzmittel |
| JPS5168569A (en) | 1974-12-10 | 1976-06-14 | Fuji Photo Film Co Ltd | 2 2 44 torimechiru 66 hidorokishi 77 chikankuromanruino seizoho |
| FR2471052B1 (fr) * | 1979-11-28 | 1985-10-11 | Kuraray Co | Photo-electrode pour cellule photo-electrochimique et son procede de fabrication |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US5220042A (en) | 1984-01-26 | 1993-06-15 | Otsuka Pharmaceutical Co., Ltd. | 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5356898A (en) | 1991-01-31 | 1994-10-18 | Warner-Lambert Company | Substituted 4,6-di-tertiary-butyl 5-hydroxy-pyrimidines |
| WO1996031217A1 (en) | 1995-04-04 | 1996-10-10 | Duke University | Inhibiting retroviral replication |
| JP2001209176A (ja) | 1999-04-02 | 2001-08-03 | Fuji Photo Film Co Ltd | 光重合性組成物およびそれを用いた記録材料 |
| WO2001062233A2 (en) | 2000-02-25 | 2001-08-30 | F. Hoffmann La Roche Ag | Adenosine receptor modulators |
| AU2001280445A1 (en) | 2000-06-23 | 2002-01-08 | Vanderbilt University | Novel chain-breaking antioxidants |
| MXPA04000613A (es) | 2001-07-20 | 2004-05-05 | Ligand Pharm Inc | DERIVADOS DE aCIDO PIRIDINILO Y PIRIMIDILTRIENOICO COMO MODULADORES DE RECEPTOR DE RETINOIDE X. |
| CA2489439A1 (en) * | 2002-06-17 | 2003-12-24 | Verification Technologies, Inc. | Materials for optical medium copy-protection transiently reacting to a reader beam |
| CA2505603A1 (en) | 2002-11-18 | 2004-06-03 | Genospectra, Inc. | Caged sensors, regulators and compounds and uses thereof |
| US20060188866A1 (en) | 2005-02-18 | 2006-08-24 | Children's Hospital Oakland Research Institute | Diaminophenothiazine compositions and uses thereof |
| EP1863796A1 (en) | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| US8268849B2 (en) | 2007-09-25 | 2012-09-18 | Board Of Regents Of The University Of Nebraska | Multifunctional Antioxidants and methods of use thereof |
| CA2906990A1 (en) | 2008-04-04 | 2009-10-08 | Duke University | Non-invasive systems and methods for in-situ photobiomodulation |
| US8389583B2 (en) | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| WO2011103536A1 (en) | 2010-02-19 | 2011-08-25 | Arizona Board Of Regents | Multifunctional radical quenchers and their use |
| JP5868955B2 (ja) * | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| EP2606022A2 (en) | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EP2450893A1 (de) | 2010-11-08 | 2012-05-09 | Bayer MaterialScience AG | Photopolymer-Formulierung zur Herstellung holographischer Medien mit hoch vernetzten Matrixpolymeren |
| WO2012125983A1 (en) * | 2011-03-17 | 2012-09-20 | Prosetta Antiviral Inc. | Antiviral treatments |
| EP2694478B1 (en) | 2011-04-04 | 2018-08-22 | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University | Methylene violet analogs as multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| KR101270160B1 (ko) | 2011-05-16 | 2013-05-31 | 아주대학교산학협력단 | 가변색 이광자 형광프로브, 이를 이용한 미토콘드리아 내 티올 활성의 영상화 방법 및 이의 제조방법 |
| WO2013120040A1 (en) | 2012-02-10 | 2013-08-15 | Children's Medical Center Corporation | Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy |
| WO2013120081A1 (en) | 2012-02-10 | 2013-08-15 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | 1h- pyrrolo [2, 3 -b] pyridine derivatives and their use as radical quenchers |
| WO2014055629A1 (en) | 2012-10-03 | 2014-04-10 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona | Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| AU2013329171A1 (en) | 2012-10-10 | 2015-04-30 | Arizona Board Of Regents, On Behalf Of Arizona State University | Multifunctional radical quenchers |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10472340B2 (en) | 2015-02-17 | 2019-11-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted phenothiazines as mitochondrial agents |
| AU2016220153B2 (en) | 2015-02-17 | 2020-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| WO2017218537A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| US10745366B2 (en) | 2016-08-25 | 2020-08-18 | Arizon Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
-
2016
- 2016-02-17 US US15/550,282 patent/US10472340B2/en active Active
- 2016-02-17 CA CA2976776A patent/CA2976776C/en active Active
- 2016-02-17 AU AU2016220096A patent/AU2016220096B2/en active Active
- 2016-02-17 EP EP16752964.3A patent/EP3258938B1/en active Active
- 2016-02-17 JP JP2017561611A patent/JP6807337B2/ja not_active Expired - Fee Related
- 2016-02-17 WO PCT/US2016/018233 patent/WO2016133995A1/en not_active Ceased
- 2016-02-17 DK DK16752964.3T patent/DK3258938T3/da active
-
2019
- 2019-10-21 US US16/659,308 patent/US11034662B2/en active Active
-
2020
- 2020-04-29 AU AU2020202836A patent/AU2020202836B2/en not_active Ceased
- 2020-10-07 JP JP2020169793A patent/JP7113055B2/ja not_active Expired - Fee Related
-
2021
- 2021-02-22 AU AU2021201137A patent/AU2021201137A1/en not_active Abandoned
- 2021-04-28 US US17/243,005 patent/US20220081404A1/en not_active Abandoned
-
2022
- 2022-07-25 JP JP2022118006A patent/JP2022141896A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7113055B2 (ja) | 2022-08-04 |
| AU2020202836B2 (en) | 2020-12-17 |
| AU2021201137A1 (en) | 2021-03-11 |
| EP3258938A1 (en) | 2017-12-27 |
| JP2021006573A (ja) | 2021-01-21 |
| JP2022141896A (ja) | 2022-09-29 |
| CA2976776A1 (en) | 2016-08-25 |
| US20200115355A1 (en) | 2020-04-16 |
| US20180065941A1 (en) | 2018-03-08 |
| AU2016220096B2 (en) | 2020-01-30 |
| US11034662B2 (en) | 2021-06-15 |
| AU2016220096A1 (en) | 2017-08-31 |
| EP3258938B1 (en) | 2020-12-02 |
| US10472340B2 (en) | 2019-11-12 |
| AU2020202836A1 (en) | 2020-05-21 |
| US20220081404A1 (en) | 2022-03-17 |
| EP3258938A4 (en) | 2018-10-31 |
| JP6807337B2 (ja) | 2021-01-06 |
| CA2976776C (en) | 2023-06-20 |
| JP2018505228A (ja) | 2018-02-22 |
| WO2016133995A1 (en) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290823A (en) | Pharmaceutical compositions for combination therapy | |
| IL282304A (en) | Topical pharmaceutical compositions | |
| IL260383B (en) | Low dose therapeutic treatment | |
| DK3328880T3 (da) | Terapeutiske midler | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
| EP3344318A4 (en) | Patient interfaces | |
| EP3522966A4 (en) | PATIENT INTERFACES | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| DK3265421T3 (da) | Doseringssystem | |
| PL4070788T3 (pl) | Formulacje farmaceutyczne | |
| HUE054344T2 (hu) | Gyógyászati készítmények AZD9291 tartalommal | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3380146T3 (da) | Medikamentadministrationsanordning | |
| EP3424940A4 (en) | Radiolabeled drug | |
| EP3246047C0 (en) | COMBINATION MEDICATION | |
| EP3437644A4 (en) | MEDICINE | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3334447A4 (en) | CCK2R-drug conjugates | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| EP3305294A4 (en) | AQUEOUS MEDICINE |